10
Dec
2019
Biotechs Build on Single-cell Analytics for Drug R&D, as Human Cell Atlas is Mapped
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
5
Dec
2019
Aural Pleasures, 2019 Edition
I listen to a lot of audio, spoken word content that edifies (or at least distracts) me during daily workouts and when traveling. Traditionally in December, I like to share with readers my annual podcast recommendations. But in reflecting on my listening habits of the last year, I realized that I’ve probably spent at least as much time listening to...Read More
Share:
3
Dec
2019
Sticking With Epigenetics During Lean Times: Jigar Raythatha on The Long Run
Today’s guest on The Long Run is Jigar Raythatha. Jigar is the CEO of Cambridge, Mass.-based Constellation Pharmaceuticals. This company is built to develop drugs against epigenetic targets. Simply put, this is a way to turn genes on or off without altering the underlying DNA. The pharmaceutical industry fancied this idea about a decade ago, as a way to shut...Read More
Share:
2
Dec
2019
IFM, Staying Small, Raises (Merely) $55.5M, Promotes Former Novartis Exec to CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
26
Nov
2019
Tamping Down Inflammation & Synaptic Dysfunction in Alzheimer’s: John Alam on The Long Run
Today’s guest on The Long Run is John Alam. John is the co-founder and CEO of Cambridge, Mass.-based EIP Pharma. This is a small company running clinical trials to test an unconventional idea for the treatment of Alzheimer’s. The gist is that if you can tamp down certain kinds of inflammation, you might be able to stop some of the...Read More
Share:
21
Nov
2019
AI Can Help with Repeatable Processes, But Don’t Expect Thunderbolts for Drug Discovery
Biopharmaceutical and healthcare executives increasingly find themselves attending conferences and presentations featuring the evangelistic selling of AI by self-assured VCs, energetic entrepreneurs, and earnest consultants. The promise is that AI will change everything. Then the executives return to work, face the quotidian reality of their operation, and wonder whether AI will change anything. Enter Jim Manzi. Manzi, depending on your view, is a...Read More
Share:
19
Nov
2019
Running the KRAS Marathon with Wellspring, and Visualizing a Second-Half Kick
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
18
Nov
2019
Feeding Frenzy: The Ecosystem is Growing Stronger
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
14
Nov
2019
Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
12
Nov
2019
Scientist, Entrepreneur, Rock Collector: Tim Springer on The Long Run
Today’s guest on The Long Run is Tim Springer. Tim wears many hats. First and foremost, he’s a scientist. An immunologist to be specific, at Harvard Medical School. He’s best known for his discovery of integrins, a class of transmembrane receptors. Now in his early 70s, Tim recently won the Gairdner Award, sometimes called the Canadian Nobel. The prize committee...Read More
Share:
12
Nov
2019
Don’t Pull Back on Basic Biology for Psychiatry: It’s Time to Double Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
11
Nov
2019
Disruption, Fast and Slow
Chris Gibson, the CEO and co-founder of Recursion Pharmaceuticals, may have captured the essence of the difference in mindset between tech VCs and life science VCs, writing in a superb recent article (a response to my previous TR post): “The most consistent thread that differentiates tech and life science VCs is their willingness to project new data onto an industry and imagine resultant...Read More
Share:
7
Nov
2019
Takeda’s Busy Week, Halozyme’s Stumble, and New FDA Commish On Deck
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
5
Nov
2019
Tech VCs and Biotech VCs: Talking Past Each Other on AI Drug Discovery
[Editor’s Note: this is a new column called “Astounding HealthTech” by TR contributor David Shaywitz.] If you want to know the difference between tech venture capitalists and biotech VCs, look at their respective views on AI applications for drug discovery. Many of the most prominent AI drug discovery startups boast exceptionally rich valuations, driven by the enthusiastic participation of tech...Read More
Share:
4
Nov
2019
New Gene-Editing Candidates Target Blood Disorders, as Gene Therapies Start to Hit the Market
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
31
Oct
2019
Amgen’s Bet on BeiGene, David Hung’s Megaround, & Zolgensma Speed Bump
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
29
Oct
2019
The Story of Henri Termeer: John Hawkins and Jim Geraghty on The Long Run
Today’s guests on The Long Run are John Hawkins and Jim Geraghty. John is a biotech industry veteran and the vice chairman of Odgers Berndtson, an executive recruiting firm in New York. He’s also the author of the new biography on Henri Termeer, the longtime CEO of Genzyme and one of the founding fathers of the biotech industry. Jim Geraghty...Read More
Share:
28
Oct
2019
Early Cancer Screening is Maturing. What Will It Mean for Drug Developers?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
24
Oct
2019
Vertex’s Watershed for CF, Biogen’s Head-Scratcher, and Seattle Genetics Nails HER2Climb
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
21
Oct
2019
Biotech’s film making exec behind ‘Jim Allison: Breakthrough’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: